Elevance Health pairs a durable 14-state Blue Cross moat with Carelon’s expanding services engine, creating an attractive long-term return profile despite near-term government-plan resets and medical-cost uncertainty.
Overview
Elevance Health operates two complementary businesses: Health Benefits, spanning commercial, ACA, Medicare, and Medicaid coverage, and Carelon, which provides pharmacy, specialty infusion, behavioral, and other care services. It covers approximately 44.88 million medical members and serves more than 104 million consumers enterprise-wide, with exclusive BCBS branding in 14 states. Q3 2026 revenue was $50.44 billion, up 0.7% year over year and 3.1% above consensus; adjusted EPS of $6.99 rose 15.9% and beat estimates by about 48.9%. The beat requires qualification: roughly $0.50 per share came from core operations and $1.85 from non-operating benefits. The Benefit Expense Ratio improved 70 basis points to 90.6%, while the operating expense ratio rose 90 basis points to 11.4%. Management raised 2026 adjusted EPS guidance to at least $29.00 and operating cash-flow guidance to at least $6.5 billion, and reaffirmed at least 12% adjusted EPS growth in 2027 from a baseline of at least $26.75. At about $430, the stock trades at approximately 14.83x FY2026 adjusted EPS. **Carelon’s higher-margin growth and a potential 2027 government-plan recovery are the central catalysts;** a five-year probability-weighted target is $716.02, though medical costs and regulatory oversight remain material risks.